The enzymatic processing of AXL leads to the production of sAXL, and plasma sAXL is significantly increased in HCC and PDAC, making it a candidate biomarker for early diagnosis of these cancers [52–55], thus highlighting the potential value of sAXL in cancer diagnosis and prognosis prediction. This evidence concerns the gene AXL and cancer.